We’re a multi-award winning biotechnology company that was formed to support doctors treat a wide range of diseases by tapping into the power of the bacterial populations flourishing inside the human gut. The company is strategically located in the heart of the University of Aberdeen’s health science complex, one of the largest healthcare campuses in Europe.
We have a committed and talented team that is developing and commercialising a pipeline of products for use in a medical treatment called Faecal Microbiota Transplantation (FMT).
To support our scientific and commercial development, we have appointed a world class independent Scientific and Medical Advisory Board as well as forged high profile research collaborations with leading academic institutions.
Whilst Faecal Microbiota Transplantation (FMT) is a NICE approved medical treatment that is remarkably effective in treating recurrent C.difficile infection, costs and logistical factors currently prevent doctors from administering it to patients.
At the present time, there is no national donor registry or infrastructure in place to deliver donated faecal material to doctors for use in the treatment. This means that doctors have to source donors and process faecal donations themselves. This process is time consuming, inefficient and not standardised.
Our immediate aim at EuroBiotix is to reduce the costs and inconveniences currently associated with providing FMT by manufacturing unlicensed medicinal products that doctors can use in the procedure. Our long term aim is to develop a suite of tools and technology that allows doctors to take a more personalised approach to FMT.